Pharmaceuticals

PTMG Spring Conference

Trade Mark Partner Rachel Havard and Consulting Patent Attorney Julie Barrett Major will represent the firm at the Spring Pharmaceutical Trade Marks Group conference in Porto, Portugal from 18th – 20th March. PTMG is a not for profit organisation and their primary objective is to enable members to meet at regular intervals to consider problems… Read more »

12th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry

Consulting Patent Attorney Julie Barrett-Major and Trainee Patent Attorney Lucy O’Brien will attend the 12th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry on 26th and 27th of February 2018 in London. ‘The conference is a specially organized two day event which will provide a multi-channel communication platform that brings together both “producers”… Read more »

The ‘Bell’ report

Recent governmental report on the UK Life Sciences Sector A report to the UK government[1] has recently published, with the aim of bringing into focus the next 20 years of UK government policy in the ‘health life sciences’ sector. In the context of the report, ‘health life sciences’ refers to the application of biology and… Read more »

Partner Craig Turner successfully defends Lycored’s European patent

In response to an opposition by chemicals company BASF, Craig Turner, a partner in our Chemistry, Biotechnology and Pharmaceutical patents team, successfully defended Lycored’s European patent which protects their unique lycopene formulation, used for providing stable red colouring for foods, cosmetics and pharmaceuticals. Longstanding client Lycored are a market-leader in the development and supply of research-based,… Read more »

Wrong number for Napp Pharmaceuticals in UK Buprenorphine infringement cases

Background Napp Pharmaceuticals (Napp) is the proprietor of a European (UK) patent, EP2305194B (the Patent), which provides protection for transdermal buprenorphine patches. Napp have marketed buprenorphine patches under the trade name “BuTrans®” since 2005. Both Sandoz and Dr Reddy’s were preparing to launch generic transdermal buprenorphine patches in the UK, but Sandoz were the first… Read more »

Global Pharma IP Forum

Global Pharma IP

Christopher Burnett, Patent Attorney attended the Global Pharma IP Forum at the London Stock Exchange on 28 September.

Categories

Archives